>> dan? >> she's sogood at mark. she's so bad at acronyms. let's just be clear on that. target is interesting here. >> guy? >> i hate the mets, as you know, but you have to give them their just due. big win, congrats. take a look at what, mel? >> at what, mel? the nasdaq. happy 25-year anniversary. "mad money" starts right now. my mission is simple. to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere, and i promise to help you find it. "mad money" starts now. >> hey, i'm cramer. welcome to "mad money." welcome to cramerica. other people make friends. i'm just trying to make a little money. my job is not just to entertain, but to teach. call me at 1-800-743-cnbc or tweet me @jimcramer. what can i say about this third quarter, the one we just put paid to. come on, it was a wacky, crazy

three months where the unthinkable kept happening. dow inches up 17 points. s&p advancing 0.42%. the months of july, august, september gave us some outstanding returns. ♪ hallelujah ♪ but the notorious month of september, especially among the worst months of the year actually delivered terrific results with the s&p gaining 2.8%. nasdaq jumping 2.86%. >> house of pleasure. >> today jay powell spoiled the bullish era saying the fed isn't in a hurry to cut rates. that's likely the next point woken be a 50 point, but who knows? the data gets worse, maybe they'll change their mind. my view, this whole parlor game of secondguessing is mostly a waste of time. the market was weaker throughout the day and then got very ugly

when powell dropped a hold on a second bomb, and then soaring. i think the late-day rally showed the market's true colors. the world is usually filled with polarizing and sad days. we know that. we can easily come up with reasons why the stocks should have been down for the session, if not the month or the whole quarter. the easiest tale for me to tell is here is five reasons why the market got oh bliterated. sell, sell, sell. >> that never happened the problem is that's bad journalism. see, when i was a cub reporter for the tallahassee democrat, i learned that bad news sells, but good news, not so off about in the newspaper biz. that's how my late editor explained how i had to write tough homicide articles, or gruesome details about plane crashes, or lurid tidbits about the deaths of movie stars. i just wanted to make good stories with the sordid tales.

but here i am on "mad money," trying to do something different. in the world where the horrid news writes itself, whether we're talking the middle east or the hurricane-ravaged parts of carolina and the big bend in florida, good news feels like a scarce commodity to me. my late editor, he knew what people would read. he knew the cereal box on the paper in the morning, the more prurient my stories were, the less likely frosted flakes would dominate the breakfast table conversation. so at the risk of telling some good news, let me give you seven positive stories. seven wonders of the world, or at least seven of the third quarter. first, there was no hard landing. there wasn't even a soft landing. there was no landing at all. the economy never stopped growing. inflation moved down. unemployment moved up. can we get rid of the airplane dichotomy? the goal should never have been a soft landing. it should have been growth with

little inflation. that's exactly what powell gave us. well done, chief. second, powell managed to do something that is borderline impo impossible. he enacted a double cut. there was a little back and forth about the possibility of 25 or 50 basis point cut when "the wall street journal" reported a double cut was possible. you know, that was perfect. just a great leak to the journal. because when we got 50, it didn't cause a panic. powell is the least drama of any fed chief i can recall, and i recall a bunch of them. he is patient to a fault with the press. i say good for him. ♪ hallelujah ♪ going into this past quarter, we've been struggling endlessly with the market that only seemed to care about the magnificent 7. when would the rally broaden out to the other 493 stocks of the s&p 500. the small caps soared. the market broadened. there were many stocks that rallied, and a lot of money was

made gray the seven. banks, utilities, retail, health care, housing, transports, they all had their day in the sun. no more narrow market, people. wall street came in the third quarter liking the same old same old. it came out liking everything, including the same old same old. get this. nvidia, it took it on the chin. showing you that ceo jensen huang is still human, even if i insist head be called the modern day da vinci. the guy is a true modern renaissance man. chairman of market and investment strategy for jp morgan calls the most polarized election in 100 years -- >> sell, sell, sell, sell, sell, sell! >> the market chose to ignore the drama. the market didn't even treat the biden debate fiasco as a speed bump. and just about an ounce of trepidation when we got the change from biden to harris. as to the attempted the assassination of donald trump. but wall street might have been located on another planet. fifth we actually had our first

break in the inflation figures as we finally begin to see extra homes coming on the market. i think the new housing supply might be the break we need that refuses to go down in price. right now it is tipping in powell's favor. at last! six, the war in the middle east is raging and the world is going lower? suffice it to say, most people would not assume that was to be occur. i kept hearing that we would have stagflation led by oil. dream on, bears. didn't happen. seven, the chinese market managed to put together a real rally, despite the economic news being overwhelmingly horrible. president xi got stocks higher when the government ordered buybacks and a lot of free money. now the chinese market had a gigantic move. now we know that many u.s. investors will pile, in take the chinese out of some really awful positions. bad move, but it will help china bolster their ailing economy. anything nuclear, we desperately

need more electricity to feed the data center beast. i was worried about the spun out, but i thought it might be a bust. eli lilly climbed. but not a single food or beverage company saw a decline in sales. talk about a wonder. starbucks got a new ceo brian niccol and the stock went up 20 points and never gave back. more on that in a moment. all the ugly duckling housing stories turned into beautiful swans. bottom line, for once, good news was actually good news. and interesting. you'd much rather talk about the driven third quarter at the breakfast table than focus on what's written on the box, back of a cereal box, wouldn't you? so the next time you start to feel horrible about the state of the world, remember that miracles can still happen, at least in the stock market's third quarter. let's take questions. let's go to robert in new york. robert? >> caller: jim, jim! how you, today, jim? >> robert, i'm doing okay. what's happening with you, partner? >> i'm doing really well.

i was out on my boat today and everybody is how do you afford this boat. and i said it's very simple. you listen to cramer. you get some great stock advice, and you make smart decisions that cramer tells you what to do. >> robert, i'm looking at my staff, and i always say that when robert calls, he's got horse sense. >> caller: jim, i'm telling you exactly the facts. and let me tell you something. enough powell indicates further rate cuts. you said you can't fight the fed. i listen to you religiously. >> thank you. >> caller: the market drive was one of the greatest investors of our time, and that was his thing. >> that was his thing. and don't fight the tape either. don't fight the fed. don't fight the tape. >> caller: because everybody says -- everybody says oh, we got to sell because they got to lower the rates. it's baked in. but cramer, as taught me through the years, that's not necessarily true. >> all right, robert. let's get a stock going and then we're really okay. >> caller: this next stock could

benefit big-time with the decrease in interest rate, not to mention the apple pay partnership that could be huge. and there are no late fees. it's the lower delinquency than any other credit cards out there, and they made the deal with apple. >> who that? >> caller: -- >> oh, a firm -- >> buy, buy, buy! >> about as powell's as affirm has. affirm is a real good stock. going higher. i like paypal too. let's go to lou, not booing in pennsylvania. lou? >> caller: hi, jim. thanks for taking my call. >> of course. >> caller: such an outstanding and competent staff. >> so smart. and i missed them last week. i was telling my wife i miss mid staff. jim, will you give me a break? but i did. okay. go ahead. >> caller: what makes your show really function so smoothly. i appreciate it. >> thank you. >> caller: i'm calling to get your opinion about a large

pharma company. you've sold in the past, which is down about 2% despite a good day today, over the last three months. it's slightly best known for the glp-1 drugs for diabetes and obesity, but its price is now a bit of beast itself. maybe it should take some of its own medication. there are several new upcoming competitors, but also no indications on the horizon. the company of course is littlely. w lilly. what are your thoughts? >> the ability it has by building these gigantic factories which costs a fortune. it reminds me of the way intel used to be in the heyday. i remain steadfast on eli lilly for my charitable trust. and i urge you to read some stuff about eli lilly. thank you for the kind comments about my staff. oh, about our staff, because it's not my staff, it's our staff. for once, good news was actually

good news. and it was able to send stocks higher in the third quarter, which is proof that miracles can still happen! ♪ hallelujah ♪ >> on "mad" tonight, the fda approved bristol-myers treatment for schizophrenia in adults, and i am learning about the implications of the new class of medicine. it's one we haven't seen in decades. you better listen to this. then, it's a battle of two analysts when it comes to a turnaround at starbucks. >> buy, buy, buy! >> sell, sell, sell! >> i'm laying out the bear case and where i come down. from labels to solar panels so, should investors stick with the stock? i'm checking in with the ceo. so stay with cramer! don't miss a second of "mad money." follow @jimcramer on x. have a question? tweet cramer, hash #madmentions. give us with call at ss8074cn. mi something? head to madmoney.cnbc.com.

is it me... or is work not working? at least, not the way it could work. your people are buried in busy work. and you might be thinking... can ai make it all work? it can. on the servicenow platform, ai transforms your entire business. your people work better, your customers are happier, and todd... well... he's practically euphoric. practically. so, let's get to work. (♪♪) (man) look at this silly little sailboat... these men of means with their silver spoons,get to work. eating up the financial favors of the 1%. what would become of them when they discover robinhood gold allows others to earn their very liberal rates on idle cash, unlimited deposit bonuses and handsome retirement matching? they would descend into chaos.

merciless chaos. business. it's not a nine-to-five proposition. it's all day and into the night. it's all the things that keep this world turning. it's the go-tos that keep us going. the places we cheer. trust. hang out. and check in. they all choose the advanced network solutions and round the clock partnership from comcast business. powering more businesses than anyone. powering possibilities.

i got some really good news. it was big breakthrough on the mental health front last friday when the fda approved bristol-myers's new drug. this represents a whole new class of drugs, the first novel treatment for schizophrenia in 30 years. that's good news because drugs have horrifying side effects. facial tic, but make you sleep 14 hours a day. that's why so many people struggle to stay on their meds. the cure is almost as bad as the disease. but this drug doesn't have these effects. bristol-myers paid 13 million to get their hands on this drug. i think it's worth every penny. this drug could help them get there. don't take it from me.

let's go to dr. chris boerner. he is chairman and ceo of bristol-myers, learn more about this amazing drug. dr. boerner, welcome back to "mad money." >> jim, thanks having me. we are thrilled with the approval and the opportunity to bring this innovative medicine to patients with schizophrenia. this is one of the things we've been focused on in my first year as ceo. and have to say, we're transforming this company to deliver long-term growth, and this is a big piece of that. >> now, when i met you, my first reaction when you told me about this is listen, be careful. the brain, everything that goes wrong with the brain, it's almost impossible to figure. why did you so much confidence to spend so much money on caruna? >> we acquired the drug because the science is so incredible here. this is a new approach to treating schizophrenia. this is a patient population that is in desperate need of something new. there hasn't been anything fundamentally new in decades. this is a patient population as you point out that have horrendous side effects with existing therapies.

you've got being tired all the time, not being able to focus, significant weight gain. for patients, many in their late teens and 20s, these are potentially debilitating side effects. and this drug does not have those. because of the way it operates, we're seeing best in line but without the side effects. that's why we're so excited to bring the medicine to patients. >> a lot of people say why don't people or schizophrenics stay on their darn meds. it's been worse than the disease sometimes. >> that's precisely right. a million and a half patients in the united states are treated with schizophrenia. over 3/4 discontinue therapy and they do so because of side effects. that's why there is so much promise in this medicine not having side effects. >> we got approval for this. there are other indications, and i don't want to get you in trouble. i don't want anyone to think you would ever go for off-label stuff. but there have to be some studies that you're doing for some of the illnesses that are

let's say adjacent to this? >> one of the things we really liked about karuna is with cobenify, you have a new mechanism. we think it has the potential in bipolar disorder, potentially alzheimer's disease psychosis. we're even seeing the potential for cognition benefit in alzheimer's disease and maybe autism spectrum disorders. so we've got a robust development program which we're prosecuting very quickly. >> all right. so let's talk about the total adjustable market if all these worked out. and we know we can't assure that they do. but now you're talk about millions on millions of people thinking is a potentially very big opportunity for us to help a lot of patients across a series of diseases in desperate need of innovation like schizophrenia. i mentioned a million and a half patients who are being treated today, and they're being suboptimally treated. and that's what we're so excited about with cobenfy. there is potential opportunity across a spectrum of diseases, and that's why we were so excited with the kruna

transaction, which we did as one of. >> the toughest stuff. i work with the american brain foundation. you have numbers you're using, but there could possibly be millions more. but there is so much stigma with problems with the brain that people say hey, i got schizophrenia, what have you got for me? >> i have to tell you, this is one of the most exciting things about this product is we can destigmatize this disease. this is such a golden opportunity. again, the first new innovation in decades. we're incredibly excited about the potential to help a lot of schizophrenia patients today. we have an additional indication in schizophrenia which will be combination use next year. there is a ton of potential to help patients initially in schizophrenia and then across a host of diseases. >> you know when you made that position, i was very excited. you wanted to walk me back a little. you said listen, we do have some patent issues that you should bring out. it was you who brought them out. what awaits the next two, three, four years?

and is the dividend safe given how tough these can get? >> listen, jim, we are incredibly excited about the long-term potential of the company. we're facing a number of patent challenges. but keep in mind a few things. first, we're not the first company to go through this. we've had big patents that we've had to address in the past. we know how to do this. but what do you have to have? first you have to have a portfolio and a pipeline that can give you growth. >> right. >> we have that. you have to have a strong financial position. we have a great balance sheet, including a very strong dividend. and you have to execute. and that's what we're squarely focused on. and we do that, i'm very confident we can navigate the next few years and exit this decade as one of the fastest growing companies. >> let people know what is something that right now produces billions that might go down because of the way generics infringe? >> well, right now we're addressing the revlomid patent expiring. a good deal while it lasted so to speak.

the nice thing about revlomid that it generates a lot of cash that can be reinvested in new opportunities and that's what we've done. the nice thing is, jim, we've got the core foundations to grow this company. we've got a strong pipeline. we've got a good growth drivers today that can help us over time compensate for the loss of patent patent exclusivity. we can continue with internally and bring in assets externally if it makes sense. >> how do we explain to people why this drug at its price is actually -- i don't want to call it a bargain, but is so important that should it be priced like this? >> well, listen, cobenfy is a funnel breakthrough. and we've priced this thread the needle. reward the innovation, but also ensure that we get broad access with this product. as you well know, innovation without access is not innovation at all.

and so we've been focused on first ensuring patients have access. we've been working with payers for months to ensure there are no undue hurdles. and we've got a very, very robust patient assist program that comes in if any patient experiences problems. we're focused on delivering this innovation to patients as quickly as possible and ensuring broad access. >> once again, i want people know, weight gain. no terrible restless leg, no. tics, no. none of this. >> we don't see any of the side effects typically associated with this class. and what's important is we see best in class efficacy without those side effects. >> that's why $1800 a month, it's not that bad versus the alleged standard of care was before you went after this. >> yes, that's exactly right, jim. we look at this as a golden opportunity to change the conversation around schizophrenia. we have the innovation to do it. and right now we're ready for this launch, and we are squarely focused on delivering this to

patients. >> thank you. >> it's my pleasure to be here. >> absolutely. that's chris boerner, ceo of bristol-myers. "mad money" back in a moment.

ref you suck! ref you suck! ref you suck! you blew the game for us! you just cost us the game! ...the worst call in the history of this sport. he should never be allowed to ref... (♪♪) ♪ i tell ya... ♪ (♪♪) ♪ how much i love you, love you, love you ♪ (♪♪)

♪ i believe. ♪ (♪♪) ♪ i believe. ♪ ♪ i believe in you. ♪ ♪ as of three weeks ago, starbucks is under new management. in mid-august, the seattle-based coffee chain gave former ceo

lak lakshman the boot. and hired brian niccol. he formally took charge three weeks ago. i'm a huge fan of this man. he is a turnaround artist, exactly what starbucks needs right now. the stock starts from $77 to $97 in change since his appointment with the vast bulk of those gains coming pretty much immediately. but not everybody is on board with the new leadership. last week while we were out two, different sell side analysts took the exact opposite side on starbucks. last tuesday jefferies led by bayerische downgraded to hold to underperform, meaning sell. [ booing ] while slashing the price target down from $80 to $76. good luck with that. and then just two days later, a different team of analysts at bernstein led upgraded the stock from market perform to outperform. meaning hold to -- >> buy, buy, buy! >> they raised the price target

from $92 to $115. personally, i have to tell you i love these-faces. i like to go put them against each other because they let you pit the best arguments of the bulls and the bears against each other, allowing you to make better informed decisions about the stock in question, and also of course making a much better stock picker. let's start with the bear case from jefferies. will take some time to brew a fresh pot. the jefferies analyst argues despite all the enthusiasm for brian niccol, the fact is turnarounds take time and they're also expensive. so any efforts to improve the business will hurt the company's near-term earnings power. okay. they say they saw the stock had gained $25 billion in market caps since we learned niccol was coming in, and they think that's, quote, too much too soon, end quote. okay. jefferies recognized starbucks' very real problems. and can't fix them overnight and can't fix them for free. in the end, jefferies argues that the earnings estimates for starbucks needs to come down.

more importantly, they expect management will give low ball guidance for the fiscal year when the company reports in early november. that's why they cut the earnings estimates from 2025 and 2026 to levels well below the wall street consensus. that is important. and that's how they end up with the $76 price target. if they're right, then all the gains since niccol's appointment would be wrong. [ buzzer ] sobering. hey, how about the bull case from starbucks from bernstein. well, again, this is basically the exact opposite of the jefferies call. in it note titled grande comeback upgrade to outperform. they argue that the current valuation does not fully appreciate the earnings power that starbucks could unlock. they acknowledge that the turnaround will take time. but crucially they tell us, quote, we believe that it will not need to be completed for the stock to start to work, end quote. that's right. the stock market is all about expectations. if you wait until the turnaround is fully executed, you're going

to miss out on most of the gains. the whole show is pretty indicated on that concept. the bern steam say the appointment of niccol and chair will, quote this, free up management to draft a plan aimed at operational stability versus chasing growth at all costs, end quote. they said they expected additional management changes and, quote, the reduction of spans and layers in the organization to act as a catalyst for the stock amid lower general and administrative expenses and streamlined decision make. sounds good to me. >> buy, buy, buy! >> the bernstein analyst went on to qualify that the operational focus of a more streamlined starbucks will have several tangible benefits like the faster food put in your hands and value perception, improved store ambience, and purposeful innovation should result in positive traffic growth. they concede thatless customization drinks might pressure same store sales. but said that the benefits from all these other factors should lead, to and i'm going quote

here, a re-acceleration of comparable sales growth, which is exactly what you want if you're a shareholder. despite investments in labor equipment and technology, we expect the operating markets to improve to historical highs by 2028 given the sales leverage and operational efficiency unlocked by the investments, end quote. basically, bernstein is agreeing with the jefferies that earnings are coming, but more focused on the potential earnings gains in 2027 and 2028. even the bulls at bernstein believe the estimate from 2025 do need to come down. in fact, bernstein's expecting lower numbers than the bears at jeffreys for the next 12 months. however, from fiscal 2026 to fiscal 2028, they're projecting a tremendous 20% compounded annual growth rate for earnings. that would be amazing. that's how they see the stock going to 115. so where do i come down? look, we've got a substantial position in starbucks for the charitable trust, and we haven't sold a share since the news that

brian niccol was taking over. so clearly i am siding with the bulls on this one. again, i don't expect the strong fourth quarter. the new guy only started three weeks ago. i don't expect particularly good earnings in 2025 either, although i'm not sure if that means flat earnings growth or a down year. in the end, though, like the bulls at bernstein, i'm willing to look through a weak year if it means starbucks can come out the other side much stronger. and i believe brian niccol can pull that off. it doesn't mean the stock won't sell off at management's loerp expectation, something i do expect. it means i recommend buying more starbucks into weakness. in the end, have i more faith in niccol's ability to get starbucks back on track. if you look at the past six years at chipotle, some of the best things he has done creating robust digital ordering, drive-throughs to make sure they're churning through all their additional orders without creating long lines and a negative in-store experience. he is basically a through-put

expert, and through-put is the biggest problem for starbucks right now. don't forget about all the positive news out of china. this is the second largest market for starbucks and it's been a total dog. but now the chinese communist party has started aiming stimulus directly at consumers should should translate into a stronger economy and better business for companies like starbucks with big china exposure that have lost share to cheaper alternatives that will be a huge positive. here is the bottom line. when you really drill down, the bulls and bears of starbucks don't seem to disagree so much on the facts. everybody acknowledged the near-term numbers are suboptimal. it's more about emphasis. the bulls are willing to look past short-term pain because they believe in brian niccol's ability to turn this thing around. the bears don't want to take that kind of risk. as for me, i am a bull on starbucks with this new ceo. i think he's got such a great track record that he has more than earned the benefit of the doubt. niccol is worth every nickel they're paying him.

>> caller: hey, mr. cramer, it's a pleasure to talk with you. >> right back at you. >> caller: calling from a town that is turnaround. we've got the tigers in the play-offs. we've got the lions playing in monday night football. and i'm trying to see analogy here. i like a stock that has called bj's wholesale. could this thing be a champion one day like a costco? is this possibly a baby costco? >> this is a tough call. i like bj's. we go to bj's. but we're costco people. this thing sales 21 times earnings so it's a little cheaper than costco. but i think it deserves to be costco. costco is the better one. but i do want to congratulate you in detroit. it may not matter that much, but i sure like your team. and go tigers. they're pretty great. rodney in texas? >> caller: boo-yah, jim. >> boo-yah! >> caller: how are you today? >> i don't know. back from vacation. the eagles lost. i'm trying to regroup, frankly.

the mets won, which i don't really care about. but my rooster sure does. i wish i didn't care so much about sports and more about making big money for people. but right now i'm possessed by how the bad the eagles are. let's go to work. >> caller: all right. yes, sir. here is my question for you. so with the recent rate cuts we've had here and the feds coming out with their plan for the next to the end of the year, to rate cuts coming up. so my stock is airbnb. my average price is 143. what's going to happen with the rate cuts with airbnb? >> i'm so glad you put it this way. i think airbnb is one of the companies that will actually do better when rates come down and people start doing more traveling. but most importantly, this thing is run by brian chesky. he has always been very conservative. when the numbers come out, i feel pretty darn good about it. i suggest that you actually buy a little more. it's down 7% for the year, and i like it. all right. the bulls and bears on starbucks

seem to realize the company's near-term numbers are suboptimal. but i'm siding with the bulls on this one. much more ahead. the feds starting to cut and china launching a stimulus, could an economically sensitive company like h.b. fuller be benefit? i'm sitting down with the ceo. and of course all your calls and rapid-fire. it's tonight's edition of the "lightning round." so stay with cramer. take the bull by the horns, every morning with jim's top ten. the biggest headlines. earnings reports, and jim's hot stocks right to your inbox. sign up now for free at cnbc.com/top ten.

ah, these bills are crazy. she has no idea she's sitting on a goldmine. well she doesn't know that if she owns a life insurance policy of $100,000 or more she can sell all or part of it to coventry for cash. even a term policy. even a term policy? even a term policy! find out if you're sitting on a goldmine. call coventry direct today at the number on your screen, or visit coventrydirect.com.

(♪♪) behind every splenda product is a mission. helping millions of people reduce sugar from their diets. now try a sweetener grown by u.s. farmers. introducing zero-calorie splenda stevia. at splenda stevia farms, our plants are sweetened by sunshine. experience how great splenda stevia can be. grown on our farm, enjoyed at your table. (♪♪) ♪ when the fed cuts interest rates and the chinese government finally takes real action to

directly stimulate their economy, you might want to look at companies that have some economic exposure, but not too much economic exposure. companies like h.b. fuller, which makes adhesives for everything from labels on your to-go coffee order to commercial roofing products to solar panels. sloping quietly higher since the end of 2021. now back in easy mode. could it be ready to roar? let's take a look with celeste mastin, the president and ceo of h.b. fuller. welcome to "mad money." >> thank you so much for inviting us. >> this is one of the companies that i think we need to know more about, because it's consistent. it's been around forever. it's done great. and you've been a steward who has really made it diversify. so why don't you, because this is the first time, give us a little overview about the company. >> absolutely. so we are the largest pure play adhesive company in the world, jim, and we're invisible. we're in everything from baby diapers, serial boxes to aerospace and electronics, but

there are three really important things to remember about this industry and h.b. fuller. one is it's an $80 billion industry. second less than 2% of the end product cost is adhesive. and finally, h.b. fuller custom tailors a lot of the adhesives that we're selling to big oems. over half of our sku base is custom tailored. >> if it's custom tailored, you don't have that level of cyclicality that we might see from some companies. you're built in to a lot of different businesses. i know the end markets i like very much. engineering and adhesives. but hygiene, health, that has almost no economic exposure, and that's kind of what i want if we have a slowing economy. >> yeah. if we have a slowing economy, it's a very stable grower. but also, we're in the midst of a renaissance in these consumer product goods that are disposable, jim, because people want sustainability.

companies are driving sustainability and the circular economy. and so when you look at our overall product develop pipeline, over 60% of those projects are related to sustainability. >> now, you also have diversity that is concerning to me. you have a lot of china, and i've been waiting for something good to happen in china. now in the last ten days, we've actually seen a kind of an explosion in the stocks, but we've also seen dramatic stimulus. china has been a problem for you. can it possibly go to a positive? >> absolutely. so if you look at our organic growth rate in china and you strip out solar, we've had mid single digit, sometimes double-digits in some quarters growth, organic growth in china. so really, we pitch to the right places to play in china overall, electronics and automotive. solar is certainly not been that.

>> right, see, i know i wanted to mention automotive. i'm glad you brought it up. obviously in the last week we've heard nothing but negatives about automotives. but i don't know whether that necessarily impacts your business that much. >> no, it really doesn't. so we've been growing our automotive business largely through share gains. >> okay. >> both share gains in the applications in which we play, and there is a lot more adhesive used in a car than there ever used to be. but also, by really focusing on new geographies, and actually the chinese ev producers have been very successful. and we've been successful with them. >> all right. now you are tough on yourself, because you at mitt that your volumes have been disappointing. and yet at the same time, i don't know how you can necessarily outgrow your end markets. >> well, we hold ourselves to a high standard, jim. absolutely. so when we look at our markets, we want to be growing with the market and gaining share. we've been very successful

taking share. and we're going grow beyond market rates because we have a good inorganic growth strategy. our mna strategy is delivering a couple of points of growth every year. >> tell me about an area that we're very excited which is a data center chip maneuvering. you' manufacturing. >> it's great. that really is our roofing business is very involved in data center roofing. big chip manufacturing, institutions. and so we've been very successful in that space. but, again, part of that is the market demand for those products. but the other part is, again, share gain through innovation. we have a new sprayable adhesive that we -- that really saves labor in application on the roof deck. and that plus relationships with oems who are constantly innovating with has had a big impact. >> how do you get your name out, so tospeak? one of the things that when i was going over all the materials, h.b. fuller, it's almost like fuller's never

really identified within these products. so i go over the end markets. i go over engineering and adhesive, construction and adhesive. it's not like your name is plastered on any product. >> no. so what do we do? we go on "mad money." >> there you go. i think that's absolutely right. look, you're the kind of company that delivers the kind of consistent growth that a lot of people should be seeking. >> yes. >> we have way too many people who want to shoot the lights out. i just kind of want to grow over time. how many years? >> oh, 135 years. >> that's a pretty good track record. i want to thank celeste mastin, who knows where to tell the story. president and ceo of h.b. fuller. a very old company with a very new business model. and a lot of great end markets that i think are going to improve in the next couple of years. "mad money" is back after this.

♪ it is time! it's time for the "lightning round." cramer -- say stocks, buy, buy, buy, sell, sell, sell, play this sound -- [ buzzer ] and the "lightning round" is over! are you ready, skee-daddy? time for the "lightning round." let's start with mike in tennessee. mike? >> hey, jim. thank you for taking my call. >> my pleasure. >> caller: cracker barrel for quite a while and i'm tyre tire the way it's going. would you get out of cracker barrel and go into home depot? >> look, i like home depot, but i'd rather double down on cracker barrel. they're doing a good job. and did you notice the stock is starting to lift? please do not sell cracker barrel. let's go to eric in utah.

eric! >> caller: hey, how is it going? >> not bad. how you? >> caller: i'm doing great. hey, brbr the ticker, provides various nutritional products in the united states. the company offers ready to drink protein shakes. it had a pullback in july and technicals trending in the right direction, a price of sales at 4, the profit margin just below 12%. now a good time to buy? >> i don't like to punt, but i have to tell you, i do not nobelring, and i've got to do more work. wait a second, wee have to figure out how that's marketed. let me come back on bellring and do a good job. you deserve that. lisa in rhode island? >> caller: hi, thanks for having me on. >> my pleasure. >> caller: i'm calling in to see what you think about redwire stock, rdw. >> everybody wants to be in the space business, and i've got to tell you, i don't. and i'm going suggest if you

want to be an auxiliary space, go with tesla. he owns the market. i do not want to go against him. robin in jersey, robin? >> caller: hey, jim. i have a question about cava. my husband and i purchased it in may. it has been up 65% since then. buy, hold, or sell? >> no, you got to hold cava. and if it comes dow, i want you to be able to buy more. it's one of the great new concepts that we have seen in this market. let's go to bill in massachusetts. bill? >> caller: hi, jim. thanks for taking my call. >> thank you. >> caller: i'm a club member, and i was thinking about buying some more next tracker. >> next tracker does not -- i'm going use an old term from when i worked with karen cramer in vegas. [ buzzer ] this acts poorly. it is a club stock, and we had dan sugar on, and the stock acts as if it's going to have a

shortfall. until we see the next quarter, i don't want to trust it because it's one of the poorly acting stocks and i find it incredibly disturbing, incredibly disturbing. let's go to taj in florida, taj? >> caller: boo-yah from boca, jim. >> boo-yah. >> caller: waiting in line the last few times i called in. so i got to throw in a two fer this time. a local company based down here in boca, the most obvious trump's trade if he wins, go group. and the other stock is hsbc. if this is really the bottoming happening, why hasn't hbsc done anything? >> i know the hsbc. frankly, it's just okay. if you want a foreign bank, please own bank santander. that's a good one. mark? >> caller: boo-yah, jim. >> boo-yah, mark, what's up? >> caller: long-time viewer. thank you for everything you do. >> absolutely, thank you. >> caller: i saw you on a stock trading segment with carl during

the event in july, and you mentioned two stocks, one was sub72. i put it on my radar and go up slowly for a week or two, i finally pulled the trigger at 74 and made some mad profits. reaching a new 52-week and some raising the price target to 20%. jim, how long longer can the honeymoon last. >> what's the stock? >> shark ninja, sorry! >> i mentioned execution. i feel very badly that i had to be tough about that. the opposite on shark ninja. these guys execute like you wouldn't believe. i wish i had bought that for the trust instead of next tracker. but i didn't. would have, should ave, could have. what a stock. that's the conclusion of the "lightning round"! [ buzzer ] >> the "lightning round" is sponsored by charles schwab. coming up, history rhymes, but no two barrels are exactly alike. cramer explains how we've come a long way from the oil panic of generations past, next.

introducing a revolution in pain relief. absorbine junior pro, the strongest numbing pain relief available. it's the only solution with two max strength anesthetics for fast penetrating relief absorbine junior pro. nothing numbs pain more.

♪ with the middle east potentially heading into another regional war, as we head into the jewish high holidays, let's talk what's changed over the past 50 odd years. back in 1973, egypt and syria invaded israel on the holiest day of the year for the jewish people, yom kippur, and usually a tremendous success as israel was caught unready because of the holiday. if the united states hadn't intervened and resupplied israel, it might have been wiped off the map. they turned things around, though, and nixon had to talk them down from taking their army all the way to cairo. i bring this up because the yom kippur war had global reverberations. once the company started airlifting munitions to israel, the heir members of opec imposed an embargo on the united states. price quadrupled.

it's been a long time, but israel has been at war for the last year, and all along people thought something similar to cap again. even if the situation escalates on the lebanese border, opec hasn't lifted a finger. saudi arabia, the company that led the 1973 embargo actually took the moment last week to abandon its price target of $100 a barrel and decided to increase production. the saudis have resigned themselves to lower prices. not only as tensions increase, this time the price fell several percent. some of the price stabilization came from us. our company is producing 9.2 barrels a day in 1973. we now produce 2 million barrels a day. we're now the world's largest producer. we're the swing producer because we can pump out another million barrels a day if we had to. that's how we broke opec. plus, russia is producing full-out in order to finance the war against ukraine. even with sanctions, they sell the crude to china. but somebody around in 1973, it's night and day.

the oil embargo 51 years ago pummelled the economy. between the high price at the pump and the shortages, it was real big deal. so we had a tremendous amount of stagflation. some feel it with australia lost decade per the economy, specifically because of that oil embargo. in fact, there is still widespread belief that the price of oil could skyrocket at any minute. i think it's wrong, but they're not going away. a spike in oil prices could still happen, although it won't be an opec embargo this time. now that israel is shooting back at the houthi militants, i don't seem them getting more emboldened. maybe the saudis change their minds, though it's borderline impossible. the organizations that israel is fighting against are backed by iran. and saudi arabia hates iran. but for anyone who has lived through the embargo and understood its economic consequences, the actual decline in the price of oil right now, it's remarkable. more importantly, it's great for the united states. we paid a huge price to back israel 51 years ago. but with opec broken and saudi arabia more hostile to iranthan israel, that's not going top

what today. i think when we look back among other things, we may say that 2024 was the year we should have had stagflation but we didn't. and that's a big reason why the first nine months of the year were so unexpectedly terrific for the stock market. i like to say there is always a bull market somewhere. i promise to try to find it just for you right here on "mad money." i'm jim cramer. see you tomorrow. returns to the tank. you're one of the most impressive people i've seen in a very long time. marcotte: this tiny object changed everything. sharks, let us break the ice. your logo is so close to scrub daddy's. i'm doing this alone. you've got to sell, man. i will never not know how to make money. that doesn't matter! i want to buy the entire company. we would take a million. bam. you want how much? [ laughs ] -- captions by vitac -- ♪♪ narrator: first into the tank is a product designed to relieve stress and promote relaxation.